Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: Wandercraft

Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss

Wandercraft earns second FDA clearance for expanded indications of Atalante X, enabling rehab for spinal cord injury and multiple sclerosis patients.
October 24, 2025 11:51 ET | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral Solution

Woburn, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Javadin™ (clonidine hydrochloride) oral...
October 13, 2025 17:41 ET | Source: KPC Health

Dr. Jeffrey Farkas Appointed Director of Neurosciences for KPC Health

KPC Health is pleased to announce the appointment of renowned neuroradiologist Dr. Jeffrey Farkas, MD, as Director of Neurosciences.
October 09, 2025 10:08 ET | Source: Toro Neurovascular

Toro Neurovascular and Kaneka Announce Exclusive U.S. Distribution Partnership

IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Toro Neurovascular, a company pioneering advanced catheter technologies for neurovascular intervention, today announced an exclusive distribution...
October 07, 2025 02:30 ET | Source: Bioxodes

Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC

Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années...
October 07, 2025 02:30 ET | Source: Bioxodes

Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate

Former GSK and Sanofi executive, led Cervarix® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalistStrengthens Bioxodes leadership following...
September 11, 2025 02:30 ET | Source: Bioxodes

Les données positives de l’essai de phase 2a de Bioxodes montrent le fort potentiel de son candidat médicament innovant BIOX-101 dans l’AVC hémorragique

Le critère de sécurité a été atteint et des signes encourageants d’efficacité ont été observés lors de l’essai mené auprès de 23 patients touchés par un AVC hémorragiqueLes résultats suggèrent que...
September 11, 2025 02:30 ET | Source: Bioxodes

Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101

Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101 reduced hematoma volume and slowed...
August 07, 2025 08:00 ET | Source: Route 92 Medical, Inc.

Route 92 Medical Files Patent Infringement Suit Against Balt

Route 92 Medical filed a patent infringement suit against Balt alleging infringement of five U.S. patents protecting its Tenzing delivery technology.
August 06, 2025 10:00 ET | Source: Centre for Neuro Skills

Brain Injury Association of America to Honor Centre for Neuro Skills’ Dr. Mark Ashley as Luminary of the Year

Brain Injury Association of America honors Centre for Neuro Skills' Dr. Mark Ashley as 2025 Luminary of the Year for contributions in brain injury field